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Pharmacokinetics of cefetamet pivoxil and interaction
with cisapride and N-acetylcysteine
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Jochen Kotwas 2 and Hartmut Lode 1
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2Klinikum Benjamin Franklin, Freie Universitat Berlin, Berlin, Germany
Objective: To evaluate the pharmacokinetics of cefetamet pivoxil and possible interaction with N-acetylcysteine and
cisapride in healthy volunteers.
Methods: In a double-blind, randomized three-way crossover study with 12 healthy male volunteers, serum and urine
concentrations of cefetamet were determined over 12 h by a validated bioassay method after oral administration of
0.5 g cefetamet pivoxil and, randomly, placebo, 5x20 mg cisapride, or 0.6 g N-acetylcysteine.
Results: The study medications were well tolerated, although there were 10 cases of altered bowel movements, two
cases of mild, transient headache and one case of increased serum transferase levels (AST and ALT). The mean peak
serum level of cefetamet pivoxil in the placebo group was 4.86 ±1.35 mg/L. The urine recovery/24 h in the placebo group
was 41.9 ±3.8% of the oral dose. The elimination half-life was 3.56 ±0.92 h. N-Acetylcysteine had no effect on the
pharmacokinetics of cefetamet pivoxil. With concomitant administration of cisapride there was an accelerated
absorption of cefetamet pivoxit and a slightly increased Cmax of cefetamet. The Cmax values differed significantly (p<0.05l
only between the cisapride group (5.76±1.50 mgfLl and the N-acetylcysteine group (4.53±1.18 mg/Ll.
Conclusion: None of the small pharmacokinetic differences between the three groups is expected to have any
relevance in the treatment of infectious diseases with cefetamet pivoxil.
Key words: Cefetamet pivoxil, interaction, N-acetylcysteine, cisapride
Cefetamet pivoxil is an oral third-generation cephalo-
sporin which is hydrolyzed to form the active agent,
cefetamet. It is effective against many Gram-positive
and Gram-negative pathogens, including Haemophilus
infiuenzae, streptococci and a broad spectrum ofEntero-
bacteriaceae [1]. Cefetamet pivoxil has been investi-
gated in the treatment of several infectious diseases,
e.g. respiratory tract infections, pharyngotonsillitis,
urinary tract infections, otitis media and pneumonia in
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children [2-6]. Especially in respiratory tract infections
antibiotics are often combined with N-acetylcysteine,
a well-described mucolytic agent, which has also been
shown to influence several antibiotics [7,8]. Cisapride,
chemically related to metoclopramide, is an orally
administered agent which facilitates or restores motility
throughout the length of the gastrointestinal tract. It
is mainly used in gastroesophageal reflux disease,
functional dyspepsia, gastroparesis and constipation [9].
Increased motility might alter the pharmacokinetic
parameters of concomitantly administered drugs, such
as antibiotics; our hypothesis was a possible reduction
ofbioavailability due to accelerated transport along the
absorptive mucosa in the upper intestine. Therefore,
the main objective of this study was to determine
the pharmacokinetics of cefetamet pivoxil in male
volunteers after oral administration with and without
concomitant administration of cisapride and N-
acetylcysteine.
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MATERIAL AND METHODS
Volunteers
Twelve male volunteers with an age range from 23 to
41 years (mean 28±5.2 years), an average weight of
78.5±8.1 kg and an average body height of183±6 em
were included in this study after physical examination
and laboratory screening. All volunteers had normal
hepatic and renal functions (mean creatinine clearance:
100±6 mLimin/1.73 m 2) and a negative medical
history for drug abuse and for any drug allergies,
especially to f3-lactam antibiotics. None of the study
subjects took any other drug during the 2 weeks
preceding the study or during the study. Informed
written consent was obtained from all subjects. The
study was approved by the ethical committee of the
Klinikum Benjamin Franklin, Freie Universitat Berlin,
according to German law.
Study design and procedure
In a three-way crossover design with a wash-out period
of 2 weeks, each volunteer received the study
medication according to the following schedule in a
random order: (1) 0.5 g cefetamet pivoxil + placebo;
(2) 0.5 g cefetamet pivoxil + 0.6 g N-acetylcysteine; (3)
0.5 g cefetamet pivoxil + 5 x 20 mg cisapride. For N-
acetylcysteine and cisapride, the study was double blind
and placebo controlled.
Order of drug administration
Five doses of cisapride or placebo were administered
every 12 h, each dose 30 min before a meal (last dose
before a standard breakfast on profiling day). N-
Acetylcysteine or placebo was administered 30 min
after the standard breakfast, together with 200 mL
of tap water, concomitantly with cefetamet pivoxil.
Postprandial absorption of cefetamet pivoxil is known
to be much better than in the fasting state [10].
Consumption of caffeine and alcohol was prohibited
during the profiling time. Cefetamet pivoxil (EXP96
M0083 MFD09 93) in the form of capsules was kindly
supplied by Hoffmann-La Roche Grenzach-Wyhlen,
Germany; Cisapride (Ch.B.: 93F22/3F039), N-acetyl-
cysteine (Ch.B.: 326006) and placebo capsules contain-
ing lactose (Ch.B.: P 508326) were obtained from the
Klinikum Benjamin Franklin Pharmacy department,
Berlin.
Composition of the standard breakfast
The standard breakfast comprised two rolls (25 g, 8%
protein, 1% fat, 55% carbohydrate), 20 g butter (1%
protein, 83% fat, 1% carbohydrate), one slice ofsausage
(15 g, 12% protein, 52% fat), 20 g jam (64% carbo-
hydrate) and liquid (300 mL caffeine-free coffee).
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Collection and processing of samples
Blood samples of 10 mL for bioassay of cefetamet were
taken from a peripheral intravenous line prior to
administering 0.5 g cefetamet pivoxil and 15, 30 and
45 min, and 1, 1t 2, 2t 3, 4, 6, 8 and 12 h afterwards
on each profiling day. The blood samples were
centrifuged for 10 min at 1300g. All samples were
covered to protect cefetamet from light exposure. After
the agar plates were inoculated with serum, the remains
of the samples were frozen at -20°C together with the
standard solutions to be used for repeated deter-
minations in case of poorly readable results. The blank
value was recorded prior to ingestion of the antibiotic
to detect possible intrinsic activity in the serum. No
volunteer exhibited any such activity. Urine samples
were collected before and 0-3,3-6,6-12 and 12-24 h
after oral application of cefetamet pivoxil. Specimens of
the urine samples were put into sterile tubes and also
stored at -20°C together with the standard solutions
until further processing. None of the urine samples
taken prior to cefetamet pivoxil administration showed
any intrinsic antibacterial activity.
Bioassay method
A bioassay method, described by Reeves and Bywater
[11], was used to determine levels of cefetamet in
serum and urine. The test strain was Klebsiella AT
10031. The lower detection limit was determined to be
0.12 mg/L in both serum and urine. The coefficient of
variation in our tests was found to be between 3.0%
(urine at 10 mg/L) and 5.6% (serum at 1 mg/L). As a
control, we established solutions with a concentration
of 2 mg/L on each profiling day which were deter-
mined 10 times. Means and standard deviations of the
control were calculated. Each plate containing samples
was also used to once again determine the concen-
tration of the control solution, which was supposed to
be within the range of three standard deviations.
Otherwise the samples had to be processed again.
Pharmacokinetic analysis
The estimation of the parameters Cmax, Tmax and t 1/2 ,
was based on an open one-compartment model. All
other parameters were analyzed non-compartmentally
[12 -14]. Dose-dependent parameters (Cmax, AUCtot)
were calculated for each dose per 70 kg ofbody weight.
Statistical analysis
The pharmacokinetic parameters of all three groups
were compared by analysis of variance. If the F value
was significant, the Student-Newman-Keuls multiple
comparison test was used to compare the means two
by two. A p value < 0.05 was considered significant
[15] .
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RESULTS
Safety and tolerance
There were no side effects that required treatment.
None of the volunteers had to be excluded during the.
study. We noticed 10 cases of altered bowel habit, two
cases of mild, transient headache and one case (placebo
group) of increased serum transferase levels (aspartate
aminotransferase (AST) 131 U/L and alanine amino-
transferase (ALT) 110 U/L without serologic evidence
ofhepatitis A, B or C, cytomegalovirus or Epstein-Barr
virus infection. Thus we have to consider cefetamet
pivoxil as a possible cause for the increase in these
parameters.
Phannacokinetics
The main pharmacokinetic parameters are shown in
Table 1. For all groups there was a mean lag time of
approximately 21 min before absorption occurred. The
mean peak concentrations of cefetamet in serum after
administration of 0.5 g cefetamet pivoxil plus placebo,
0.5 g cefetamet pivoxil plus concomitant administra-'
tion of cisapride in steady state (5 x20 mg), and 0.5 g
cefetamet pivoxil plus concomitant administration of
0.6 g N-acetylcysteine, were 4.9 mg/L, 5.8 mg/L and
4.5 mg/L, respectively (Figure 1). A significant dif-
ference (p<O.05) was found only between the cisapride
group and the N-acetylcysteine group. This could be
explained by an accelerated Tmax in the cisapride group
Table 1 Pharmacokinetic parameters (mean±standard deviation) of cefetamet after oral administration of cefetamet pivoxil
(Cef. Piv.) according to the schedule mentioned above
Parameters
1i.g (h)
Cmu (mg/L)
Tmax (h)
1'1" (h)
AUC,o, (mg h/L)
Urine-Rec. (% of dose)
V"lf(L170 kg)
Clto.lf (mL/min/1.73 m2)
Cl«n (mL/min/1.73 m2)
. Cef. Piv. +placebo
0.36±0.lS
4.86±1.3S
3.10±0.98
3.S6±0.92
32.8±S.2
41.9±3.8
48.8±12.4
2S2±38
106±20
Cef. Piv. +NACC
0.3S±0.12
*4.53±1.18
3.34±0.73
3.24±0.81
32.9±S.8
42.9±7.2
SO.9± 16.1
2S3±46
106± 12
Cef. Piv. +Cisapride
0.3S±0.14
*S.76± 1.50
2.76±O.52
2.86±0.53
32.S±S.9
44.6±41
42.8±8.9
2S6±40
108± 11
Tl.g=lag time; Cmax=peak concentration; Tmu=time of peak' concentration; TI/,,=biological elimination' half-life; AUC=area undet the
curve; Urine-Rec.=urine recovery124 h; V;,lf=volume of distribution at steady state; Clto.lf=total clearance; Clren=renal clearance;
f= bioavailability; NACC = N-acetylcysteine; *p <0.05.
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Figure 1 Serum concentrations of cefetamet (mean±standard deviation).
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Figure 2 Cumuhltive renal recovery ofcefetamet (mean±standard deviation).
of 2.8 h, compared to 3.1 h in the placebo group and
3.3 h in the N-acetylcysteine group. The corres-
ponding 24-h urine recovery of cefetamet (Figure 2)
after concomitant cisapride administration was higher
(45%) compared with both other groups (42%, 43%),
although not significantly increased.
The biological elimination half-life was 3.6 h in
the placebo group and 2.9 h in the cisapride group
(p>0.05). There was no change in the area under the
curve (AUCtor) and the renal clearance by concomitant
administration of N-acety1cysteine or cisapride, indica-
ting that concomitant administration of neither N-
acetylcysteine nor cisapride altered the bioavailability of
cefetamet pivoxil.
DISCUSSION
The results presented above show that absorption of
orally administered cefetamet pivoxil (0.5 g) leads to
a mean peak serum concentration of cefetamet of
approximately 4.9 mg/L and a renal excretion of about
42% of the given dose. These values confirm previous
investigations on the pharmacokinetics of cefetarnet
pivoxil [16). The peak concentration of cefetamet
pivoxil is similar to the peak concentrations of other
cephalosporin esters, such as cefuroxime axetil (5.6
mg/L) , cefpodoxime proxetil (2.5 mg/L after 0.2 g
orally) and cefotiam hexetil (4.4 mg/L after 0.4 g
orally), whereas the peak concentration of cefixime is
lower (1.9 mg/L after 0.2 g orally). Loracarbef (19.2
rng/L after 0.4 g orally), ceftibuten (11.6 mg/L after
0.2 g orally) and cefprozil (9.6 mg/L) have higher peak
concentrations [17].
The n1ean elimination half-life (t1/2,) of cefetamet
pivoxil is approximately 3.6 h, which is up to threefold
longer than the elimination half-lives of cefuroxime
axetil, cefprozil and loracarbef [17]. Since the bio-
availability of cefetamet pivoxil is approximately 50%
[16], the urinary recovery of 41.9±3.8% (placebo
group) indicates a primarily renal elimination. The
mean renal clearance in the placebo group was 106
mLimin/1.73 m2. Mainly renal elimination has also
been described for most other new oral cephalosporins.
Only cefixime has a low urine recovery and a high
concentration in the bile, indicating hepatic elimina-
tion [17-19].
Our comparison of the area under the curve
(concentration x time), the most important parameter
ofbioavailability, led to the following results. After the
administration of 0.5 g cefetamet pivoxiI we observed
mean AVC values of 32.8 ± 5.2 mg h/L, similar to the
values of cefprozil (26.1 ± 0.7 rng h/L after 0.5 g
orally), cefixime (14.9±5.2 mg h/L after 0.2 g orally),
loracarbef (33.0 ± 5.9 mg h/L after 0.4 g orally) and the
new cephalosporin esters (cefuroxime axetil, 37.8 ± 7.2
rng h/L after 0.5 g; cefiJOdoxime proxetil, 14.0±3.9
mg h/L after 0.2 g, except for cefotiam hexetil with an
AVC value ofonly 9.1 mg h/L after oral application of
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0.4 g). The AUC value of ceftibuten has been shown
to be 48.3 ±5.7 mg h/L, after oral application of only
0.2g[17].
As previously reported for loracarbef [20] and
recently shown for sparfloxacin [21], the results of this
study indicate that concomitant administration of
cisapride in the steady state accelerates the absorption
of cefetamet pivoxil, thus increasing the peak serum
level. However, this difference was only significant
(p<0.05) when the N-acetylcysteine group was com-
pared with the cisapride group; nevertheless, the area
under the curve (concentration x time) of these groups
remained constant. Since Tmax in the cisapride group is
decreased compared to both other groups (not signi-
ficantly), the increase in Cmax may be due to the
accelerated gastric emptying caused by cisapride. Con-
comitant administration of N-acetylcysteine was also
investigated because the combination ofcephalosporins
and mucolytic drugs is widely used in the treatment of
respiratory tract infections, although some investigators
have reported negative in vitro effects of N-acetyl-
cysteine on antibiotics, including cephalosporins [8,9].
In this study, concomitant administration of 0.6 g N-
acetylcysteine had no effect on the essential pharmaco-
kinetic parameters (peak serum level, area under the
curve, urinary excretion) ofcefetamet pivoxil. None of
the changes in pharmacokinetics of cefetamet pivoxil
caused by the concomitant administration of cisapride
or N-acetylcysteine is expected to have any clinical
relevance in treatment of infectious diseases with
cefetamet pivoxil.
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